Meeting
2020 ASCO Virtual Scientific Program
CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.
Authors
Meghan Mooradian
Massachusetts General Hospital Cancer Center, Boston, MA
Meghan Mooradian , James M. Cleary , Justine Vanessa Cohen , Donald P. Lawrence , Elizabeth Iannotti Buchbinder , Anita Giobbie-Hurder , Aparna Raj Parikh , Geoffrey Shapiro , Lancia Darville , Keiran Smalley , John M Koomen , Amber Newton , Harold N. Keer , S. Percy Ivy , Helen X. Chen , Ryan J. Sullivan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02097225
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3609)
DOI
10.1200/JCO.2020.38.15_suppl.3609
Abstract #
3609
Poster Bd #
339
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study.
First Author: Shiraj Sen
Poster
2024 ASCO Annual Meeting
Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.
First Author: April K.S. Salama
Poster
2019 ASCO Annual Meeting
Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.
First Author: Marcelo Vailati Negrao
Poster
2017 ASCO Annual Meeting
Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.
First Author: Manisha H. Shah